drugset / Trial / NCT06366945
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficiency and safety of Tislelizumab combinated with carboplatin and polymeric micellar paclitaxel as a new neoadjuvant treatment regimen for resectable HNSCC patients with clinical positive lymph node metastasis
Timeline
- Start
- 2024-04-20
- Primary completion
- 2026-12-30
- Completion
- 2029-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Polymeric Micellar Paclitaxel | Unknown | 300 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |